Company Performance Metrics
CatchMe Therapeutics develops a novel class of precision medicines that targets the epitranscriptome machinery.
The new science of RNA posttranscriptional alterations, known as epitranscriptomics, has made significant progress over the previous ten years. The capacity to control various epitranscriptome machinery components holds considerable
promise for the development of novel therapies. New discoveries are discovered every day. According to research, the most prevalent mRNA alteration is N6-methyladenosine (m6A). A complex network of proteins that add to (writer), remove from (eraser), and bind to (reader) the m6A-modified mRNA molecules processes the modification. In many human illnesses, such as cancer and viral infections, the significance of m6A RNA alteration has been clearly established.
